Rie Maurer: Influence Statistics

Rie Maurer

Rie Maurer

BRIGHAM AND WOMEN'S, MEDICINE, BOSTON, UNITED STATES OF AMERICA | Center for Clinical Investigation, Brigham and Women's Hospital, Boston, MA, United States | The Harvard ...

Rie Maurer: Expert Impact

Concepts for which Rie Maurer has direct influence: Lymphangioleiomyomatosis lam , Sirolimus hydroxychloroquine , Patients ipf , Lam patients , Idiopathic pulmonary fibrosis , Inhaled carbon , Cox2 inhibition .

Rie Maurer: KOL impact

Concepts related to the work of other authors for which for which Rie Maurer has influence: Carbon monoxide , Lymphangioleiomyomatosis lam , Idiopathic pulmonary fibrosis , Intestinal transplantation , Pharmacological treatments , Tuberous sclerosis complex , Systemic jia .

KOL Resume for Rie Maurer

Year
2022

BRIGHAM AND WOMEN'S, MEDICINE, BOSTON, UNITED STATES OF AMERICA

2020

Center for Clinical Investigation, Brigham and Women's Hospital, Boston, MA, United States

2017

The Harvard Clinical and Translational Science Center, Boston, MA

Prominent publications by Rie Maurer

KOL-Index: 6559 . BACKGROUND: Animal and cellular studies support the importance of autophagy inhibition in lymphangioleiomyomatosis (LAM). In a cohort of subjects with LAM, we tested the hypothesis that treatment with sirolimus and hydroxychloroquine (an autophagy inhibitor) at two different dose levels is safe and well tolerated. Secondary end points included changes in lung function. METHODS: This ...
Known for Lung Function | Autophagy Inhibition | Sirolimus Hydroxychloroquine | Clinical Trial
KOL-Index: 5329 . BACKGROUND: Preclinical studies have demonstrated that low-dose carbon monoxide (CO) can abrogate experimental lung fibrosis. To test the therapeutic role of inhaled CO, we designed a clinical study in patients with idiopathic pulmonary fibrosis (IPF). METHODS: We conducted a multicenter, phase IIa, double-blinded, sham-controlled, clinical trial. Patients with IPF were randomized to ...
Known for Pulmonary Fibrosis | Patients Ipf | Carbon Monoxide | 12 Weeks
KOL-Index: 1720 . Lymphangioleiomyomatosis (LAM) is a multisystem disease associated with progressive pulmonary disease that affects almost exclusively women. LAM is characterised pathologically by proliferation of abnormal smooth muscle-like cells carrying mutations in predominantly the tuberous sclerosis complex (TSC) gene TSC2 and, rarely, in TSC1 [1]. LAM can occur sporadically or in association with ...
Known for Lymphangioleiomyomatosis Lam | Tsc Genes | Tuberous Sclerosis Complex | Mechanistic Target

Key People For Lymphangioleiomyomatosis Lam

Top KOLs in the world
#1
Joel Moss
cholera toxin adenylate cyclase tuberous sclerosis
#2
Francis X McCormack
surfactant protein tuberous sclerosis complex lymphangioleiomyomatosis lam
#3
Thomas Vail Colby
idiopathic pulmonary fibrosis interstitial pneumonia lung biopsy
#4
Jay Hoon Ryu
idiopathic pulmonary fibrosis lung disease rheumatoid arthritis
#5
Angelo M Taveira DaSilva
lung function lymphangioleiomyomatosis lam chylous effusions
#6
Simon Richard Johnson
tuberous sclerosis lymphangioleiomyomatosis lam smooth muscle

BRIGHAM AND WOMEN'S, MEDICINE, BOSTON, UNITED STATES OF AMERICA | Center for Clinical Investigation, Brigham and Women's Hospital, Boston, MA, United States | The Harvard Clinical and Translational Science Center, Boston, MA, USA | The Harvard Clinic